Autolus announces positive primary endpoint data in FELIX trial
December 13, 2022Research and Development
Autolus Therapeutic, a clinical-stage biopharmaceutical company, has announced that the phase 2 FELIX clinical trial of obecabtagene autoleucel (obe-cel) in …
Seagen shares data for Adcetris combination for Hodgkin Lymphoma
December 13, 2022Research and Development
Adcetris has long been one of Seagen’s top-selling and expanding products, and it has announced that the drug appeared successful …
RemeGen’s RC118 granted two orphan drug designations by FDA
December 13, 2022Medical Communications
Chinese commercial-stage biotechnology company RemeGen has announced that RC118 for injection – its latest antibody-drug conjugate (ADC) – has been …
New blood cancer treatment appears successful for most trial patients
December 12, 2022Research and Development
A new and experimental immunotherapy treatment has appeared successful in treating patients with multiple myeloma in an ongoing phase 1/2 …
Amgen expected to buy Horizon at valuation of $26bn
December 12, 2022Sales and Marketing
Amgen Inc is expected to acquire biotech firm Horizon Therapeutics Plc at a valuation of $26bn. This would be Amgen’s …
UK Strep A death toll rises to 15
December 9, 2022Medical Communications
Data from the UK Health Security Agency (UKHSA) show that 15 children under the age of 15 have now died …
FDA priority review given to Pfizer’s RSV vaccine for older adults
December 9, 2022Medical Communications
Pfizer has announced that the FDA has accepted its application for a respiratory syncytial virus (RSV) vaccine for older adults, …
Biocorp receives FDA 510(k) approval for Mallya device
December 8, 2022Medical Communications
French medical devices company, Biocorp, has received the FDA’s 510(k) approval for diabetes care device, Mallya. The device is a …
Novartis and MorphoSys sign $23m deal
December 8, 2022Sales and Marketing
MorphoSys has announced that it will sell its worldwide licensing rights to its preclinical cancer programme to Novartis in exchange …
AbbVie to enter deal with HotSpot for up to $335m
December 7, 2022Sales and Marketing
AbbVie and HotSpot Therapeutics have begun working on a licensing option deal for HotSpot’s preclinical small-molecule allosteric therapy, which will …
EMA accepts marketing authorisation application for ALS treatment, tofersen
December 7, 2022Sales and Marketing
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for tofersen. The drug would treat superoxide dismutase …
Positive results for BioVie’s Parkinson’s and Alzheimer’s phase 2 trials
December 6, 2022Research and Development
BioVie has announced positive results from two phase 2 trials which have been assessing NE3107’s efficacy in treating Parkinson’s Disease …
Nkarta data supports natural killer cells in cancer treatment
December 6, 2022Research and Development
San Francisco, US-based Nkarta have been assessing the power of natural killer (NK) cells in oncology treatments. The treatment is …
Aptamer Group sign deals to develop Optimer solutions
December 5, 2022Business Services
Aptamer Group has announced a selection of contracts aimed at exploring Optimer technology, which will offer new strategies for therapeutics …
Innovent Biologics and UNION Therapeutics announce first dosing of Chinese subject in phase 1 study
December 5, 2022Research and Development
Innovent Biologics, a biopharmaceutical company which develops, manufactures and commercialises medicines for the treatment of illnesses within the scope of …
Amgen’s obesity drug appears promising with few side effects
December 5, 2022Research and Development
Amgen Inc’s new obesity drug has appeared promising in its small phase 1 trial, meaning they will be able to …
New insights into HIV vaccine revealed by researchers
December 5, 2022Research and Development
Although researchers have previously always struggled to develop an efficient HIV vaccine, the results of a first-in-human clinical trial for …
Scottish Medicines Consortium approves Bayer’s Kerendia for NHS Scotland
December 2, 2022Medical Communications
The Scottish Medicines Consortium (SMC) has given the green light to Bayer’s Kerendia (finerenone), a chronic kidney disease (CKD) drug …
GSK’s two new cancer drugs look promising
December 2, 2022Research and Development
GlaxoSmithKline (GSK) appear to be making some positive progress in their oncology department, with drugs for both myelofibrosis and endometrial …
AstraZeneca and MSD launch prostate cancer awareness campaign
December 2, 2022Medical Communications
AstraZeneca and MSD (known as Merck & Co. in the United States and Canada) have announced their collaborative global prostate …
Latest content
FibroFind appoints Lee Borthwick as CEO
